{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"23","value":"778.5"}]}],"title":"C1D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"32","value":"716.9"}]}],"title":"C1D7"}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"description":"Maximum plasma concentration of azacitidine dosed in combination with glasdegib (C1D7) and when dosed alone (C1D1) in the Lead-in Cohort was estimated using non-compartmental analysis.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received SC administration of azacitidine daily at a dose of 75 mg/m2/day on Days 1-7 of every 28 days, and received oral self-administration of glasdegib daily and continuously at home with a starting dose of 100 mg QD. In Cycle 1 only, administration of glasdegib commenced on Day 2 of the cycle (C1D2) to permit DDI evaluation.","id":"OG000","title":"Lead-in Cohort"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"The PK concentration analysis set included all participants who received treatment and had at least 1 value of analyte concentration of glasdegib or azacitidine available.","reportingStatus":"POSTED","timeFrame":"0.25, 0.5, 1, 2, 6 hours post-dose on Cycle 1 Day 1, predose and 0.25, 0.5, 1, 2, 6 hours postdose on Cycle 1 Day 7","title":"Cmax of Azacitidine Dosed in Combination With Glasdegib (C1D7) and When Dosed Alone (C1D1) in the Lead-in Cohort","type":"SECONDARY","unitOfMeasure":"ng/mL"}